1Schafer AI. Antiplatelet therapy. Am J Med, 1996,101:199-209.
2Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J, 1988, 296:313-316.
3Hansson L,Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension : principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet,1998,351 : 1755-1762.
4Steering Committee of the Physicians' Health Study Research Group.Final report on the aspirin component of the ongoing Physicians'Health Study. N Engl J Med, 1989,321:129-135.
5de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice.Collaborative Group of the Primary Prevention Project. Lancet,2001,357:89-95.
6The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet, 1998, 351:233-241.
7Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med ,2005,352:1293-1304.
1Antithrombotic trialists'collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ,2002,324:71-86.
2Bertrand ME, Simoons ML, Fox KAA,et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The task force of the management of acute coronary syndromes of the European Society of Cardiology. Eur Heart J,2002,23:1809-1840.
3Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on practice Guidelines (Committee on the Management of Patients With Unstable Angina).J Am Coll Cardiol, 2000,36:970-1062.
4ETDRS investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 14. JAMA,1992,268:1292-1300.
5Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment (HOT)ranomised trial. Lancet,1998,351:1755-1762.
6Frilling B, Schiele R, Gitt AK, et al. Characterization and clinical course of patients not receiving aspirin for acute myocardial infarction: Results from the MITRA and MIR studies. Am Heart J ,2001,141:200-205.
7Sleeper RB, Rojas-Fernandez C.Underutilization of aspirin for secondary prophylaxis of cardiovasucular disease in a long-term-care facility. Am J Health-syst Pharm,2002,59:1294-1295.
8Patrono C, Bachmann F, Baigent C, et al. Expert Consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J ,2004,25:166-181.
9Montague TJ, Wong RY, Burton JR, et al. Changes in acute myocardial infarction risk and patterns of practice for patients older and younger than 70 years, 1987-1990. Can J Cardiol, 1992,8:596-600.
10Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med,1996,124:292-298.
